Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

By H. Hurwitz, L. Fehrenbacher, W. Novotny, T. Cartwright, John Hainsworth, W. Heim, J. Berlin, A. Baron, S. Griffing, E. Holmgren and 5 more. New England Journal of Medicine, 2004

9,988 citations recorded by the source corpus.

Subfields: Molecular Biology, Oncology

View Paper: https://www.semanticscholar.org/paper/4596040e87b7fe76a1d4ae09e39d52a15153e4e6

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

In Oncology

Citations in the corpus

VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. (2006, background): “The relative freedom of serious side effects in preclinical studies and in patients who were administered VEGF inhibitors is consistent with this assumption (22, 26, 29, 72).”
VEGF as a Therapeutic Target in Cancer (2005, background): “In a large randomized controlled trial, the addition of bevacizumab to standard chemotherapy for patients with previously untreated metastatic CRC resulted in a 30% increase in median survival (Hurwitz et al. 2004 [27] , described in more detail later in this issue).”
The impact of O2 availability on human cancer (2008, background): “Bevacizumab is now commonly used for the treatment of metastatic colorectal cance”
Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. (2009, result): “BV was well tolerated, and the incidence of targeted AEs in patients with glioblastoma was similar to that observed in previous BV trials.(16-19) The incidence of certain AEs, such as the rate of infection, increased with the addition of chemotherapy; however, no new safety issues related to BV or B”
Differential roles of vascular endothelial growth factor receptor-1 and receptor-2 in angiogenesis. (2006, background): “In addition to the VEGF-A neutralizing antibody, the use of which is already a standard treatment for late-stage colorectal cancer in the USA (Hurwitz et al., 2004), BAY43-9006 was recently approved by the FDA for the treatment of renal cancer patients.”
Molecular basis for sunitinib efficacy and future clinical development (2007, background): “The first approved anti-angiogenic agent to improve survival in metastatic colorectal cancer was bevacizumab (Avastin; Genentech), a recombinant humanized monoclonal antibody that prevents VEGF from binding to and activating VEGFR”
The seed and soil hypothesis revisited - the role of tumor-stroma interactions in metastasis to different organs (2011, background): “7 months.(90) A rapidly expanding body of evidence indicates that both tumor cells and host cells contribute to the resistance of therapies that are designed to block the VEGF signaling pathway.”
Non-commercial Research and Educational Use including without Limitation Use in Instruction at Your Institution, Sending It to Specific Colleagues That You Know, and Providing a Copy to Your Institution's Administrator. All Other Uses, Reproduction and Distribution, including without Limitation Comm (2005, neutral): “The purpose of the analysis is then to find the dipole–dipole couplings and chemical shielding parameters that reproduce the experimental spectrum.”
AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. (2005, background): “In combination with irinotecan, 5-fluorouracil and leucovorin, bevacizumab imparts a significant prolongation of survival and response variables in patients with first-line metastatic colorectal cancer (61).”